Evidence map›Paper›PMID 38343660›Full record

ArticleBiomedical reports2024

Assessment of the effects of amphiphilic poly (N‑vinylpyrrolidone) nanoparticles loaded with bortezomib on glioblastoma cell lines and zebrafish embryos.

Anne V Yagolovich, Andrey N Kuskov, Pavel P Kulikov, Dmitry V Bagrov, Polina A Petrova, Ekaterina V Kukovyakina, Alina A Isakova, Irina I Khan, Vadim S Pokrovsky, Alexander E Nosyrev and 5 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedical reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 2 countries.

Anne V YagolovichFaculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russian Federation.
Andrey N KuskovD. Mendeleev University of Chemical Technology of Russia, 125047 Moscow, Russian Federation.
Pavel P KulikovD. Mendeleev University of Chemical Technology of Russia, 125047 Moscow, Russian Federation.
Dmitry V BagrovFaculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russian Federation.
Polina A PetrovaFaculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russian Federation.
Ekaterina V KukovyakinaD. Mendeleev University of Chemical Technology of Russia, 125047 Moscow, Russian Federation.
Alina A IsakovaD. Mendeleev University of Chemical Technology of Russia, 125047 Moscow, Russian Federation.
Irina I KhanN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, 115478 Moscow, Russian Federation.
Vadim S PokrovskyN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, 115478 Moscow, Russian Federation.
Alexander E NosyrevCenter of Bioanalytical Research and Molecular Design, Sechenov First Moscow State Medical University, 119991 Moscow, Russian Federation.
Polyxeni C StamatiDepartment of Neurology, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41100 Larissa, Greece.
Elena A MarkvichevaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry of The Russian Academy of Sciences, 117997 Moscow, Russian Federation.
Marine E GasparianD. Mendeleev University of Chemical Technology of Russia, 125047 Moscow, Russian Federation.
Demetrios A SpandidosLaboratory of Clinical Virology, Faculty of Medicine, University of Crete, 71003 Heraklion, Greece.
Aristidis M TsatsakisCenter of Bioanalytical Research and Molecular Design, Sechenov First Moscow State Medical University, 119991 Moscow, Russian Federation.
D. Mendeleyev University of Chemical Technology of Russia · RULomonosov Moscow State University · RUMinistry of Health of the Russian Federation · RUSechenov University · RUInstitute of Bioorganic Chemistry · RUUniversity of Crete · GRUniversity of Thessaly · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proteasome inhibitor bortezomib is an anticancer agent approved for treatment of multiple myeloma and mantle cell lymphoma. However, its application in other types of cancer, primarily in solid tumors, is limited due to poor pharmacokinetics, inefficient tissue penetration, low stability and frequent adverse effects. In the present study, a novel micellar nano-scaled delivery system was manufactured, composed of amphiphilic poly(N-vinylpyrrolidone) nanoparticles loaded with bortezomib. Similar nanoparticles loaded with prothionamide, a drug without anticancer effect, were used as control. The size and zeta potential of the obtained polymeric micelles were measured by dynamic light scattering. Bortezomib-loaded micelles exhibited significant cytotoxic activity

Indexed as

amphiphilicbortezomibmicellespolymer nanop-articlespoly(N-vinylpyrrolidone)

Identifiers

PMID38343660
PMCPMC10853758
OpenAlexW4390952052

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.